Understanding the role of new systemic agents in the treatment of prostate cancer.
about
Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome.Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.Impact of curative radiotherapy on the immune status of patients with localized prostate cancerA novel prostate cancer immunotherapy using prostate-specific antigen peptides and skin test reagent as an adjuvant
P2860
Understanding the role of new systemic agents in the treatment of prostate cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Understanding the role of new systemic agents in the treatment of prostate cancer.
@en
type
label
Understanding the role of new systemic agents in the treatment of prostate cancer.
@en
prefLabel
Understanding the role of new systemic agents in the treatment of prostate cancer.
@en
P2860
P50
P356
P1433
P1476
Understanding the role of new systemic agents in the treatment of prostate cancer
@en
P2093
Damien Bolton
Jack Crozier
P2860
P356
10.1111/BJU.13633
P478
118 Suppl 3
P577
2016-10-06T00:00:00Z